Our understanding of the function of the liver has evolved over the centuries. Early theories
proposing that the liver could be used to divine the future have been superseded by our …

A significant proportion of patients who suffer from atrial fibrillation (AF) and are in need of
thromboembolic protection are not treated with oral anticoagulation or discontinue this …

Importance The influence of race and ethnicity on initiation of direct oral anticoagulants
(DOACs) is relatively understudied in Medicare data. Objective To investigate disparities in …

Background and aims The effects of direct oral anticoagulants (DOACs) in patients with non-
valvular atrial fibrillation (NVAF) and liver disease remain poorly understood. Our …

Direct oral anticoagulants (DOACs) targeting activated factor Xa (FXa) are used to prevent or
treat thromboembolic disorders. DOACs reversibly bind to FXa and inhibit its enzymatic …

Whilst advanced liver disease was previously considered to be an acquired bleeding
disorder, there is increasing recognition of an associated prothrombotic state with patients …

Purpose The popularity of direct oral anticoagulants (DOACs) is increasing among patients
with cirrhosis. Cirrhosis has a major impact on the pharmacokinetics of drugs, potentially …

Background Information regarding the safety and efficacy of specific direct oral
anticoagulants (DOAC) in the treatment of cerebral sinus and venous thrombosis (CSVT) is …

Pulmonary embolus (PE) carries a significant impending morbidity and mortality, especially
in intermediate and high-risk patients, and the choice of initial anticoagulation that allows for …

Historically, anticoagulants were contraindicated in patients with cirrhosis owing to concerns
about bleeding risks. However, recent studies have shown that patients with cirrhosis are not …